Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation

Therapies targeting the tyrosine kinase activity of Epidermal Growth Factor Receptor (EGFR) have been proven to be effective in treating a subset of non-small cell lung cancer (NSCLC) patients harboring activating EGFR mutations. Inevitably these patients develop resistance to the EGFR-targeted tyro...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Nayoung, Cho, Ahye, Watanabe, Hideo, Choi, Yoon-La, Aziz, Meraj, Kassner, Michelle, Joung, Je-Gun, Park, Angela KJ, Francis, Joshua M., Bae, Joon Seol, Ahn, Soo-min, Kim, Kyoung-Mee, Park, Joon Oh, Park, Woong-Yang, Ahn, Myung-Ju, Park, Keunchil, Koo, Jaehyung, Yin, Hongwei Holly, Cho, Jeonghee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924679/
https://www.ncbi.nlm.nih.gov/pubmed/26883194
http://dx.doi.org/10.18632/oncotarget.7318

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924679/
https://www.ncbi.nlm.nih.gov/pubmed/26883194
http://dx.doi.org/10.18632/oncotarget.7318

Ejemplares similares